Vanguard Group Inc Aveo Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$8.48 - $14.97 $46,173 - $81,511	5,445 Added 0.36%	1,513,400 $22.6 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $43,877 - $57,883	6,638 Added 0.44%	1,507,955 $12.4 Million
Q1 2022 May 13, 2022	BUY	$3.15 - $6.01 $114,061 - $217,622	36,210 Added 2.47%	1,501,317 $8.39 Million
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $41,633 - $65,689	8,877 Added 0.61%	1,465,107 $6.87 Million
Q3 2021 Nov 12, 2021	BUY	$5.12 - $6.89 $43,745 - $58,868	8,544 Added 0.59%	1,456,230 $9 Million
Q2 2021 Aug 13, 2021	BUY	$6.21 - $7.45 $8.99 Million - $10.8 Million	1,447,686 New	1,447,686 $9.54 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.